These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12413824)

  • 21. Break with tradition.
    Jayaraman KS
    Nature; 2006 Jul; 442(7101):342-3. PubMed ID: 16871181
    [No Abstract]   [Full Text] [Related]  

  • 22. Golden opportunities.
    Smaglik P
    Nature; 2005 Jul; 436(7047):144-7. PubMed ID: 16007735
    [No Abstract]   [Full Text] [Related]  

  • 23. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
    Rai AK; Reichman JH; Uhlir PF; Crossman C
    Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer?
    Kaski JC
    Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624
    [No Abstract]   [Full Text] [Related]  

  • 25. More fizz at Pfizer?
    Nature; 2006 Aug; 442(7104):734. PubMed ID: 16915258
    [No Abstract]   [Full Text] [Related]  

  • 26. Patent highlights October-November 2017.
    Mucke HA
    Pharm Pat Anal; 2018 Mar; 7(2):73-81. PubMed ID: 29417883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trimmed down Chiron pitches cancer genomics.
    Hodgson J
    Nat Biotechnol; 1998 Dec; 16(13):1308. PubMed ID: 9853602
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug discovery through industry-academic partnerships.
    Gray NS
    Nat Chem Biol; 2006 Dec; 2(12):649-53. PubMed ID: 17108976
    [No Abstract]   [Full Text] [Related]  

  • 29. 13th EGA annual conference. Challenges in the European and global environment for the generic medicines industry.
    Kuhrt K
    IDrugs; 2007 Aug; 10(8):549-53. PubMed ID: 17665329
    [No Abstract]   [Full Text] [Related]  

  • 30. Charles Hugh-Jones. Interview by Asher Mullard.
    Hugh-Jones C
    Nat Rev Drug Discov; 2013 Dec; 12(12):900. PubMed ID: 24287774
    [No Abstract]   [Full Text] [Related]  

  • 31. Cancer research in the United States: A critical review of current status and proposal for alternative models.
    Kantarjian HM; Prat F; Steensma DP; Kurzrock R; Stewart DJ; Sekeres MA; Leveque J
    Cancer; 2018 Jul; 124(14):2881-2889. PubMed ID: 29757456
    [No Abstract]   [Full Text] [Related]  

  • 32. Bioversity 2007.
    McGee V
    IDrugs; 2007 Aug; 10(8):554-6. PubMed ID: 17665330
    [No Abstract]   [Full Text] [Related]  

  • 33. How to kill synthetic biology.
    Sci Am; 2006 Jun; 294(6):4. PubMed ID: 16711348
    [No Abstract]   [Full Text] [Related]  

  • 34. Patents.
    Ruiz NV; Oranias Olsina G
    Int Rev Neurobiol; 2010; 94():35-66. PubMed ID: 21081201
    [No Abstract]   [Full Text] [Related]  

  • 35. Opening up the Ivory Tower.
    Wilan KH
    Cell; 2007 Jun; 129(5):847-50. PubMed ID: 17540161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Industrial-strength bonds.
    Nature; 2015 Nov; 527(7577):S76-9. PubMed ID: 26560455
    [No Abstract]   [Full Text] [Related]  

  • 37. Multicompany trials adapt to disciplines beyond cancer.
    Mullard A
    Nat Med; 2014 Jan; 20(1):3. PubMed ID: 24398947
    [No Abstract]   [Full Text] [Related]  

  • 38. Should platform companies move toward products?
    Ratner M
    Nat Biotechnol; 1999 Jan; 17(1):16-7. PubMed ID: 9920255
    [No Abstract]   [Full Text] [Related]  

  • 39. Redesigner drugs.
    Dove A
    Nat Biotechnol; 2004 Aug; 22(8):953-7. PubMed ID: 15286643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Collaborating with academia: what you need to know.
    Dinunzio MC; Wilson AE; Pokotilow SB
    J Biomol Screen; 2002 Aug; 7(4):391-3. PubMed ID: 12230894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.